realiti
adher
intern
confer
harmonis
ich
guidanc
expect
new
vaccin
subject
welldefin
regulatori
process
approv
approv
process
consist
four
princip
element
prepar
preclin
materi
proofofconcept
test
anim
model
manufactur
clinic
materi
accord
current
gmp
toxicolog
analysi
appropri
anim
system
chapter
outlin
basic
manufactur
vaccin
descript
exampl
current
licens
product
move
regulatori
requir
vaccin
manufactur
includ
current
gmp
complianc
discuss
develop
new
vaccin
final
section
examin
great
challeng
field
deliv
product
held
everincreas
standard
safeti
provid
suffici
dose
reason
cost
everincreas
number
diseas
manufactur
vaccin
compos
sever
basic
step
result
finish
product
tabl
summar
step
exampl
pathogen
licens
vaccin
first
step
gener
antigen
use
induc
immun
respons
step
includ
gener
pathogen
subsequ
inactiv
isol
subunit
gener
recombin
protein
deriv
pathogen
vaccin
develop
use
addit
method
discuss
later
virus
grown
cell
either
primari
cell
chicken
fibroblast
eg
yellow
fever
vaccin
continu
cell
line
eg
hepat
vaccin
bacteri
pathogen
grown
bioreactor
use
medium
develop
optim
yield
antigen
maintain
integr
recombin
protein
manufactur
bacteria
yeast
cell
cultur
viral
bacteri
seed
cultur
cell
line
use
viral
product
care
control
store
character
often
protect
first
step
manufactur
establish
master
cell
bank
collect
vial
cell
form
start
materi
futur
product
extens
character
perform
absenc
adventiti
agent
bank
work
cell
bank
prepar
use
routin
start
cultur
product
lot
final
vaccin
direct
function
start
materi
chang
seed
complic
initi
new
product
develop
altogeth
phillip
l
gomez
jame
robinson
advers
environment
condit
particularli
temperatur
extrem
vari
depend
composit
live
attenu
vaccin
tend
suscept
inactiv
vaccin
toxoid
vaccin
formul
potenc
end
shelflif
remain
effect
dose
demonstr
human
clinic
trial
product
may
degrad
year
shelf
life
releas
target
potenc
may
significantli
specifi
endofshelflif
specif
overformul
repres
signific
product
yield
loss
costofgood
increas
final
product
order
support
necessari
lead
time
deliv
store
vaccin
especi
use
rotat
stockpil
protect
suppli
interrupt
emerg
use
materi
addit
stabil
lyophil
feasibl
tend
improv
thermal
resist
vaccin
storag
low
temperatur
within
manufactur
suppli
chain
may
use
reduc
potenc
loss
storag
although
recommend
storag
condit
mani
vaccin
detail
vaccin
manufactur
respons
develop
data
licens
demonstr
stabil
vaccin
recommend
storag
condit
claim
shelf
life
gener
program
provid
data
excess
claim
shelf
life
year
support
develop
new
product
intend
clinic
use
well
routin
support
current
market
product
expir
date
extens
support
distribut
condit
acceler
studi
conduct
elev
temperatur
commonli
appli
better
understand
impact
transient
temperatur
excurs
vaccin
manufactur
requir
assur
product
control
maintain
appropri
condit
ident
strength
qualiti
puriti
product
affect
current
limit
number
vaccin
requir
feder
regul
specifi
ship
temperatur
although
vaccin
manufactur
use
insul
contain
precaut
brief
usual
hour
ship
time
occasion
unanticip
temperatur
excurs
may
occur
could
detriment
impact
ship
product
accept
vaccin
shipment
user
look
evid
improp
transport
condit
includ
excess
transport
time
possibl
advers
ambient
temperatur
condit
influenza
viru
vaccin
intramuscular
use
steril
suspens
prepar
influenza
virus
propag
chicken
embryo
vaccin
primari
method
prevent
influenza
sever
complic
typic
influenza
vaccin
contain
two
strain
influenza
virus
singl
influenza
b
viru
addit
strain
influenza
b
viru
ad
first
fourantigencontainingvaccin
licens
two
type
virus
identifi
subtyp
hemagglutinin
neuraminidas
hemagglutinin
neuraminidas
glycoprotein
influenza
viru
compris
major
surfac
protein
princip
immun
antigen
viru
protein
insert
viral
envelop
spikelin
project
ratio
approxim
trival
subunit
vaccin
predomin
influenza
vaccin
use
today
vaccin
produc
viral
strain
identifi
earli
year
world
health
organ
center
diseas
control
prevent
next
step
releas
antigen
substrat
isol
bulk
environ
use
growth
isol
free
viru
secret
protein
cell
cell
contain
antigen
spent
medium
next
step
purif
antigen
vaccin
compos
recombin
protein
step
may
involv
mani
unit
oper
column
chromatographi
ultrafiltr
inactiv
viral
vaccin
may
simpli
inactiv
isol
viru
purif
formul
vaccin
design
maxim
stabil
vaccin
deliv
format
allow
effici
distribut
prefer
clinic
deliveri
product
formul
vaccin
may
includ
adjuv
enhanc
immun
respons
stabil
prolong
shelf
life
andor
preserv
allow
multidos
vial
deliv
formul
consist
combin
compon
constitut
final
vaccin
uniformli
mix
singl
vessel
fig
oper
conduct
highli
control
environ
employe
wear
special
protect
cloth
avoid
contamin
adventiti
agent
control
monitor
environ
critic
surfac
conduct
oper
qualiti
control
qc
test
stage
usual
consist
safeti
potenc
puriti
steril
assay
specif
product
phase
individu
scrupul
clean
depyrogen
singledos
multidos
contain
fill
vaccin
seal
steril
stopper
plunger
vaccin
lyophil
vial
stopper
insert
partial
allow
moistur
escap
lyophil
process
vial
move
lyophil
chamber
vial
receiv
outer
cap
stopper
contain
closur
integr
preclud
introduct
extran
viabl
nonviabl
contamin
fill
oper
must
take
place
highli
control
environ
peopl
equip
compon
introduc
critic
area
control
manner
fill
contain
inspect
use
semiautom
autom
equip
design
detect
minut
cosmet
physic
defect
formul
phase
vaccin
manufactur
oper
extens
control
monitor
environ
critic
surfac
conduct
oper
qc
test
stage
also
consist
safeti
potenc
puriti
steril
assay
may
specif
product
vaccin
efficaci
advers
affect
improp
distribut
storag
condit
sensit
vaccin
separ
hydrophob
interact
sizeexclus
chromatographi
result
hbsag
assembl
lipoprotein
particl
hbsag
purifi
greater
protein
seri
physic
chemic
method
purifi
protein
treat
phosphat
buffer
formaldehyd
steril
filter
coprecipit
alum
potassium
aluminum
sulfat
form
bulk
vaccin
adjuv
amorph
aluminum
hydroxyphosph
sulfat
vaccin
contain
detect
yeast
dna
may
contain
yeast
protein
second
recombin
hepat
b
vaccin
surfac
antigen
express
cerevisia
cell
purifi
sever
physiochem
step
formul
suspens
antigen
absorb
aluminum
hydroxid
procedur
use
manufactur
result
product
contain
yeast
protein
substanc
human
origin
use
manufactur
vaccin
hepat
b
prepar
recombin
yeast
cultur
noninfecti
free
associ
human
blood
blood
product
lot
hepat
b
vaccin
test
safeti
mice
guinea
pig
steril
qc
product
test
puriti
ident
includ
numer
chemic
biochem
physic
assay
final
product
assur
thorough
character
lottolot
consist
quantit
immunoassay
use
monoclon
antibodi
use
measur
presenc
high
level
key
epitop
yeastderiv
hbsag
mous
potenc
assay
also
use
measur
immunogen
hepat
b
vaccin
effect
dose
capabl
seroconvert
mice
ed
calcul
hepat
b
vaccin
steril
suspens
intramuscular
inject
vaccin
suppli
four
formul
pediatr
adolescenthighrisk
infant
adult
dialysi
formul
contain
approxim
mg
aluminum
provid
amorph
aluminum
hydroxyphosph
sulfat
per
millilit
vaccin
tabl
summar
qc
test
requir
releas
recombin
hepat
b
vaccin
vaccin
still
releas
cber
lotbylot
basi
sever
extens
character
vaccin
hepat
b
human
papillomaviru
hpv
vaccin
manufactur
use
recombin
dna
process
requir
elimin
manufactur
process
includ
signific
purif
extens
character
analyt
method
addit
hepat
b
vaccin
demonstr
track
record
continu
safeti
puriti
potenc
qualifi
exempt
cdc
cber
uslicens
manufactur
viral
strain
normal
acquir
cber
cdc
european
strain
typic
provid
nation
institut
biolog
standard
control
southern
hemispher
strain
therapeut
good
administr
australia
viral
strain
use
prepar
cell
bank
manufactur
cell
bank
ultim
use
inoculum
vaccin
product
substrat
commonli
use
produc
influenza
vaccin
embryon
chicken
egg
monoval
viru
suspens
receiv
cber
cdc
monoval
viru
suspens
pass
egg
inocul
egg
incub
specif
time
temperatur
regimen
control
rel
humid
harvest
european
union
number
passag
origin
sampl
limit
harvest
allanto
fluid
contain
live
viru
test
infect
titer
specif
steril
fluid
store
wet
frozen
extrem
low
temperatur
maintain
stabil
monoval
seed
viru
msv
msv
also
certifi
cber
msv
introduc
egg
autom
inocul
viru
grown
incub
temperatur
allanto
fluid
harvest
purifi
highspe
centrifug
sucros
gradient
chromatographi
purifi
viru
often
split
use
deterg
final
filtrat
viru
inactiv
use
formaldehyd
primari
purif
step
depend
manufactur
repeat
three
four
strain
viru
individu
test
releas
inactiv
viral
concentr
combin
dilut
final
vaccin
strength
inactiv
viru
vaccin
describ
use
major
flu
vaccin
produc
sold
today
recent
year
inactiv
influenza
vaccin
produc
mammalian
cell
cultur
approv
number
countri
process
replac
eggbas
viru
expans
certifi
cell
line
downstream
process
similar
focus
remov
host
cell
protein
dna
design
threshold
recombin
influenza
vaccin
produc
insect
cell
infect
recombin
baculoviru
express
hemagglutinin
protein
also
approv
unit
state
juli
recombin
hepat
b
vaccin
licens
unit
state
vaccin
built
knowledg
heatinactiv
serum
contain
hepat
b
viru
hbv
hepat
b
surfac
antigen
hbsag
infecti
immunogen
partial
protect
subsequ
exposur
hbv
hbsag
compon
confer
protect
hbv
immun
produc
vaccin
gene
code
hbsag
gene
insert
express
vector
capabl
direct
synthesi
larg
quantiti
hbsag
saccharomyc
cerevisia
hbsag
particl
express
purifi
yeast
cell
demonstr
equival
hbsag
deriv
plasma
blood
hepat
b
chronic
carrier
recombin
cerevisia
cell
express
hbsag
grown
stir
tank
ferment
medium
use
process
complex
ferment
medium
consist
extract
yeast
soy
pepton
dextros
amino
acid
miner
salt
inprocess
test
conduct
ferment
product
determin
percentag
host
cell
express
construct
end
ferment
process
hbsag
harvest
lyse
yeast
cell
product
haemophilu
influenza
type
b
hib
conjug
includ
separ
product
capsular
polysaccharid
hib
carrier
protein
tetanu
protein
clostridium
tetani
ie
purifi
tetanu
toxoid
crm
viral
protein
express
heterolog
system
effect
pathogen
often
poor
immunogen
incorrect
fold
modif
viruslik
particl
vlp
design
mimic
overal
structur
viru
particl
thu
preserv
nativ
antigen
conform
immunogen
protein
vlp
produc
wide
rang
taxonom
structur
distinct
virus
uniqu
potenti
advantag
term
safeti
immunogen
previou
approach
attenu
inactiv
vlp
requir
particularli
import
epitop
commonli
modifi
inactiv
treatment
howev
viral
vector
eg
baculoviru
use
express
system
inactiv
may
requir
purif
process
elimin
residu
viral
activ
vlp
realist
vaccin
candid
need
produc
safe
express
system
easi
scale
largescal
product
accompani
purif
inactiv
process
maintain
nativ
structur
immunogen
meet
requir
today
global
regulatori
author
number
express
system
manufactur
multimer
vlp
includ
baculoviru
express
system
bve
high
five
cell
escherichia
coli
aspergillu
niger
chines
hamster
ovari
cell
human
function
liver
cell
babi
hamster
kidney
cell
transgen
plant
potato
tobacco
soybean
cerevisia
pichia
pastori
human
embryon
kidney
cell
lupin
callu
plantcel
product
system
yield
rang
high
e
coli
purifi
bve
proven
quit
versatil
demonstr
capabl
prepar
vaccin
candid
papillomaviru
felin
caliciviru
hepat
e
viru
porcin
parvoviru
chicken
anemia
viru
porcin
circoviru
simian
viru
polioviru
bluetongu
viru
rotaviru
hepat
c
viru
hiv
simian
immunodefici
viru
felin
immunodefici
viru
newcastl
diseas
viru
sever
acut
respiratori
syndrom
sar
coronaviru
hantaan
viru
influenza
viru
infecti
bursal
diseas
viru
mani
pathogen
virus
influenza
hiv
hepat
c
surround
envelop
membran
consist
lipid
bilay
deriv
host
cell
insert
viru
glycoprotein
spike
protein
target
neutral
antibodi
essenti
compon
vaccin
owe
inher
properti
lipid
envelop
assembl
vlp
insect
cell
viral
vaccin
differ
type
technic
challeng
produc
virus
multipl
capsid
target
product
vlp
challeng
task
synthesi
assembl
one
recombin
protein
may
requir
case
vlp
rotaviru
rna
viru
capsid
form
monom
four
differ
protein
addit
product
vlp
requir
simultan
express
assembl
sever
recombin
protein
case
rlp
need
occur
singl
host
cell
purif
vlp
also
constitut
particularli
challeng
task
vlp
structur
sever
nanomet
diamet
molecular
weight
rang
da
also
guarante
qualiti
product
suffici
demonstr
absenc
contamin
protein
also
necessari
show
protein
correctli
assembl
vlp
product
hpv
vlp
repres
anoth
challeng
hpv
type
major
capsid
protein
produc
certain
recombin
express
system
cerevisia
form
irregularli
shape
vlp
broad
size
distribut
hpv
vlp
inher
unstabl
tend
aggreg
solut
primari
challeng
hpv
vaccin
polysaccharid
select
dissoci
disrupt
past
increas
ionic
strength
polysaccharid
purifi
phenol
extract
ultrafiltr
ethanol
precipit
final
materi
precipit
alcohol
dri
vacuum
store
process
tetanu
protein
prepar
bioreactor
use
approv
seed
c
tetani
crude
toxin
recov
cultur
supernat
continuousflow
centrifug
diafiltr
crude
toxin
purifi
combin
fraction
ammonium
sulfat
precipit
ultrafiltr
result
purifi
toxin
detoxifi
use
formaldehyd
concentr
ultrafiltr
store
process
industri
conjug
process
initi
develop
use
tetanu
toxoid
team
head
jb
robbin
nation
institut
allergi
infecti
diseas
niaid
bethesda
maryland
conjug
prepar
twostep
process
involv
activ
hib
capsular
polysaccharid
b
conjug
activ
polysaccharid
tetanu
protein
spacer
activ
includ
chemic
fragment
nativ
polysaccharid
specifi
molecular
weight
target
coval
linkag
adip
acid
dihydrazid
activ
polysaccharid
coval
link
purifi
tetanu
protein
carbodiimidemedi
condens
use
carbodiimid
purif
conjug
materi
perform
obtain
highmolecularweight
conjug
molecul
devoid
chemic
residu
free
protein
polysaccharid
conjug
bulk
dilut
appropri
buffer
fill
unitdos
andor
multidos
vial
lyophil
measl
viru
isol
part
genu
morbilliviru
famili
paramyxovirida
current
vaccin
deriv
edmonston
moraten
schwarz
strain
vaccin
market
sinc
combin
measl
mump
rubella
mmr
sinc
final
vaccin
live
attenu
viral
vaccin
induc
immun
recipi
one
measl
vaccin
manufactur
vaccin
start
specif
pathogenfre
embryon
chicken
egg
incub
sever
day
embryo
collect
treat
trypsin
prepar
chick
embryo
fibroblast
cell
cultur
oper
done
strict
asept
condit
perform
welltrain
oper
cell
cultur
grown
roller
bottl
use
fetal
calf
sera
hank
media
optim
cell
growth
chick
embryo
fibroblast
cell
infect
viral
work
seed
incub
sever
day
viral
cultur
end
viral
cultur
cell
disrupt
mechan
lysi
releas
viru
viru
purifi
centrifug
filtrat
store
frozen
releas
qc
test
vaccin
formul
alon
mump
rubella
vaccin
lyophil
obtain
stabl
product
vaccin
reconstitut
use
manufactur
use
differ
cell
substrat
exampl
serum
institut
india
use
human
diploid
cell
manufactur
measl
vaccin
see
http
wwwseruminstitutecomcontentproductsproduct
mvachtm
tradit
viral
vaccin
reli
attenu
viru
strain
inactiv
infecti
viru
subunit
vaccin
base
manufactur
smaller
scale
manufactur
system
enabl
singleus
technolog
enabl
competit
price
signific
time
advantag
smaller
facil
promis
technolog
clear
trigger
signific
invest
equip
develop
singleus
space
singleus
promis
signific
howev
number
hurdl
new
technolog
format
glass
stainless
steel
equip
histor
manufactur
process
gener
inert
contribut
impur
manufactur
process
polym
use
singleus
equip
may
differ
reactiv
product
extract
leachabl
shown
shed
particul
shown
tendenc
leak
mani
concern
overcom
time
polym
engin
alter
product
techniqu
next
abil
elimin
high
cost
clean
steril
equip
requir
entir
system
singleus
mani
process
abl
make
convers
yield
low
yield
mean
high
volum
volum
l
challeng
weight
hydrostat
pressur
pressur
high
demand
aerat
volum
flow
rate
solvent
use
temperatur
control
heat
transfer
limit
chromatographi
also
challeng
process
singleus
system
although
promis
advanc
increas
option
prepack
column
promis
dynam
pace
advanc
singleus
system
manufactur
face
plethora
option
jigsaw
puzzl
part
connect
effect
industri
rather
new
standard
necessari
allow
interconnect
part
still
margin
gain
attent
standard
develop
extract
leachabl
particul
classif
manag
integr
supplier
evalu
interchang
govern
sponsor
agenc
includ
parent
drug
associ
bioprocess
system
allianc
extract
leachabl
safeti
inform
exchang
product
qualiti
research
institut
intern
societi
pharmaceut
engin
american
societi
test
materi
unit
state
pharmacopeia
name
manag
standard
key
effect
use
integr
technolog
support
vision
singleus
reliabl
conting
suppli
robust
suppli
chain
limit
surpris
chang
manag
one
major
advantag
rightsiz
singleus
process
abil
support
distribut
manufactur
today
vast
major
suppli
vaccin
come
hand
develop
countri
cost
complex
largescal
facil
profit
market
support
signific
manufactur
clinic
invest
public
compani
necessari
licens
manufactur
vaccin
larg
facil
built
duplic
signific
challeng
complex
support
system
essenti
make
everi
facil
uniqu
advent
lowcapit
singleus
manufactur
platform
support
scaleout
process
built
offtheshelf
singleus
system
truli
duplic
origin
licens
process
minim
challeng
provid
equival
product
new
facil
origin
facil
one
also
imagin
make
clinic
materi
modest
scale
avoid
challeng
scaleup
market
could
leverag
addit
multipl
singleus
bioreactor
instead
larg
stainless
system
demand
grow
approach
support
payasyougo
capit
approach
avoid
larg
invest
prior
demonstr
proof
concept
promis
make
formul
develop
prepar
aqueou
hpv
vlp
solut
stabl
varieti
purif
process
storag
condit
treat
hpv
vlp
process
disassembl
reassembl
stabil
vitro
potenc
vaccin
enhanc
significantli
addit
vivo
immunogen
vaccin
also
improv
much
approxim
shown
mous
potenc
studi
disassembl
reassembl
particl
may
also
import
remov
residu
protein
express
system
host
cell
use
product
seriou
process
challeng
particularli
envelop
vlp
vaccin
develop
involv
process
take
new
antigen
immunogen
identifi
research
process
develop
substanc
final
vaccin
evalu
preclin
clinic
studi
determin
safeti
efficaci
result
vaccin
process
product
compon
inprocess
materi
final
product
specif
manufactur
process
defin
manufactur
scale
use
develop
usual
significantli
smaller
use
final
manufactur
process
phase
sometim
phase
ii
clinic
trial
vaccin
typic
produc
product
develop
usual
anticip
least
one
three
consist
lot
use
phase
iii
clinic
trial
manufactur
fullscal
product
volum
product
manufactur
develop
phase
manufactur
accord
current
gmp
earli
vaccin
produc
vivo
eg
infect
calv
cowpox
rabbit
rabi
viru
inde
influenza
viru
vaccin
still
made
chicken
embryo
use
neat
purifi
larg
glass
lab
equip
later
anim
cell
use
viral
vaccin
grown
vitro
eg
roller
bottl
infect
amplifi
viru
viral
vaccin
later
cell
grown
microcarri
deep
cultur
enabl
high
manufactur
volum
effici
microbi
vaccin
produc
larg
l
bioreactor
larger
scale
product
process
stainless
steel
equip
purif
largescal
product
use
increas
capac
meet
increas
demand
lifesav
product
cost
facil
increasingli
expens
past
decad
system
increasingli
complex
autom
clean
steril
valid
facil
manufactur
larg
central
manufactur
facil
enabl
lower
cost
manufactur
higher
volum
need
lower
high
fix
cost
construct
valid
oper
larg
central
facil
increasingli
effici
also
limit
manufactur
limit
number
site
develop
countri
higher
product
yield
new
manufactur
techniqu
increas
focu
person
medicin
nich
product
eg
lowvolum
product
rare
diseas
allow
new
paradigm
smaller
manufactur
facil
bioreactor
advent
dispos
singleus
equip
elimin
high
cost
clean
steril
manufactur
equip
reduc
complex
cost
manufactur
facil
allow
econom
addit
challeng
world
health
organ
guidelin
use
wildtyp
polio
viru
necessari
manufactur
ipv
given
potenti
accid
manufactur
could
releas
wildtyp
polioviru
environ
recommend
limit
wildtyp
manufactur
ipv
geographi
high
ipv
coverag
surround
commun
least
three
dose
environ
low
transmiss
potenti
current
vaccin
global
vaccin
come
india
china
supplier
vaccin
focus
lowcost
product
deliveri
vaccin
geographi
current
option
ipv
manufactur
base
gapiii
recommend
varieti
strategi
current
develop
field
address
challeng
includ
focu
manufactur
technolog
util
manufactur
ipv
opportun
increas
product
reduc
unit
cost
exist
polio
vaccin
manufactur
process
develop
year
ago
use
stainless
steel
fix
infrastructur
manufactur
process
newer
singleus
technolog
allow
lower
cost
initi
facil
design
could
use
polio
vaccin
manufactur
analysi
lope
colleagu
show
use
newer
facil
design
approach
includ
singleus
technolog
reduc
bulk
ipv
cost
predominantli
reduc
capit
cost
facil
anoth
approach
decreas
cost
increas
product
manufactur
process
optim
cell
cultur
condit
use
altern
cell
line
evalu
suggest
much
higher
titer
wildtyp
viru
could
drive
cost
vaccin
thomassen
colleagu
show
vero
cell
cultur
optim
increas
product
dantigen
threefold
crucel
present
data
show
humanderiv
cell
line
product
time
higher
vero
cell
current
use
manufactur
ipv
allow
broader
manufactur
polio
vaccin
altern
vaccin
use
sabin
attenu
strain
inactiv
also
pursu
sabinipv
sipv
virus
shown
lower
yield
cell
cultur
work
done
optim
express
purif
yield
work
focus
celllin
select
optim
facil
design
importantli
use
sipv
allow
broader
geograph
set
potenti
locat
manufactur
includ
india
china
substanti
manufactur
infrastructur
vaccin
focus
lowcost
manufactur
initi
discoveri
polio
vaccin
requir
innov
manufactur
method
enabl
launch
ultim
erad
polio
requir
innov
manufactur
enabl
full
public
health
impact
vaccin
given
complex
develop
vaccin
difficult
target
like
hiv
tuberculosi
tb
malaria
new
tool
emerg
use
primeboost
strategi
vaccin
concept
use
one
vaccin
prime
follow
use
entir
differ
vaccin
boost
notabl
hiv
vaccin
efficaci
trial
thailand
posit
result
use
approach
thai
trial
prime
recombin
canarypox
vector
follow
recombin
protein
boost
neither
canarypox
recombin
protein
shown
efficaci
combin
gave
posit
result
trial
approach
use
product
avail
broadli
quickli
licens
global
partnership
distribut
facil
nearer
market
serv
well
align
current
develop
polici
multipl
emerg
economi
selfreli
essenti
servic
like
vaccin
suppli
exampl
agreement
glaxosmithklin
brazil
describ
sale
glaxosmithklin
pneumococc
conjug
vaccin
brazil
year
agreement
transfer
manufactur
process
brazil
potenti
use
futur
year
distribut
manufactur
approach
mani
benefit
includ
limit
global
suppli
shortag
catastroph
event
singl
plant
abil
custom
product
region
eg
strain
organ
chang
region
offset
cost
manufactur
potenti
paid
govern
taxgener
local
job
challeng
consid
maintain
align
process
among
multipl
facil
challeng
biolog
manufactur
process
process
drift
singl
plant
multipl
manufactur
plant
increas
chanc
least
one
plant
drift
licens
proven
process
likewis
control
raw
materi
qualiti
sourc
singleus
compon
suppli
chang
supplier
materi
compon
similar
unintend
unexpect
consequ
leav
region
without
suppli
issu
identifi
resolv
singleus
system
ever
improv
keep
specif
need
process
may
challeng
multipl
small
purchas
equip
versu
larg
central
organ
manag
regulatori
file
divers
product
approach
within
singl
compani
across
compani
singl
product
may
also
difficult
regul
spite
challeng
note
benefit
distribut
model
advanc
standard
within
singleus
manufactur
solut
come
experi
expand
use
sure
make
realiti
time
manufactur
polio
vaccin
began
ultim
result
two
product
wide
distribut
salk
inactiv
polio
vaccin
ipv
sabin
live
attenu
polio
vaccin
opv
opv
manufactur
typic
cell
line
minim
purif
postharvest
combin
rel
high
product
dose
liter
capac
result
lower
cost
manufactur
risk
vaccineassoci
paralyt
poliomyel
vapp
estim
per
million
threedos
schedul
plan
transit
salk
ipv
polio
come
closer
erad
ultim
make
switch
howev
requir
substanti
increas
capac
manufactur
ipv
without
product
improv
would
requir
substanti
increas
cost
deliv
polio
vaccin
target
popul
product
ipv
describ
tabl
show
viru
must
grown
cell
cultur
purifi
use
three
chromatographi
step
follow
inactiv
bioprocess
step
result
loss
materi
reduc
overal
product
altern
opv
manufactur
cell
line
minim
purif
addit
dose
live
viral
vaccin
typic
much
lower
inactiv
one
also
help
product
process
reflect
price
vaccin
unicef
publish
price
vaccin
procur
opv
vial
serum
institut
india
wherea
ipv
bilthoven
biologicalsserum
institut
india
fivedos
vial
vaccin
cite
hiv
tb
malaria
use
product
separ
organ
ultim
vaccin
prove
success
need
singl
regulatori
licens
holder
respons
distribut
vaccin
requir
care
collabor
differ
organ
licensur
lifecycl
manag
vaccin
primeboost
vaccin
test
earli
clinic
trial
design
see
earli
efficaci
signal
vaccin
given
limit
focu
futur
manufactur
suppli
chain
product
cost
even
earli
stage
clinic
studi
howev
import
ensur
partnership
clearli
defin
among
vaccin
develop
clinic
studi
design
demonstr
true
requir
primeboost
regim
characterist
compon
must
elicit
immun
earli
cost
model
help
target
invest
process
develop
ensur
success
signal
efficaci
test
ultim
result
vaccin
success
manufactur
distribut
target
popul
final
challeng
coordin
suppli
chain
two
separ
vaccin
requir
complet
immun
potenti
differ
immun
time
deploy
suppli
vaccin
synchron
demand
routin
immun
rel
straightforward
catchup
mass
vaccin
campaign
requir
care
manag
expir
date
plan
vaccin
suppli
shortag
unfortun
uncommon
requir
multipl
vaccin
increas
possibl
one
might
continu
avail
creat
partial
immun
potenti
offschedul
immun
individu
implic
scenario
may
explor
phase
ii
dose
studi
postmarket
surveil
refer
chapter
avail
expertconsultcom
addit
hiv
vaccin
efficaci
test
tb
vaccin
malaria
among
other
sever
challeng
aris
use
primeboost
vaccin
need
overcom
use
futur
licens
vaccin
distribut
first
complex
multival
vaccin
success
batch
releas
primeboost
vaccin
like
multival
vaccin
requir
success
manufactur
releas
multipl
compon
exampl
hiv
vaccin
develop
vaccin
research
center
nation
institut
health
nih
hiv
test
efficaci
contain
six
plasmid
dna
compon
prime
five
recombin
adenoviru
vector
boost
requir
product
separ
activ
pharmaceut
ingredi
must
combin
two
separ
formul
test
failur
one
compon
delay
abil
combin
materi
manufactur
final
product
yield
individu
compon
consequ
cost
vari
wide
requir
uniqu
manufactur
suppli
chain
design
provid
consist
suppli
project
demand
critic
compon
assay
develop
vaccin
develop
potenc
assay
releas
two
vaccin
requir
efficaci
test
defin
exactli
potenc
requir
compon
import
clinic
studi
ensur
futur
batch
distribut
meet
criteria
may
requir
primeboost
immunogen
evalu
anim
batch
releas
decreas
improv
vitro
method
potenc
evalu
vaccin
final
primeboost
approach
often
involv
multipl
organ
compani
vaccin
compani
focu
core
set
vaccin
platform
technolog
allow
build
expertis
process
develop
assay
develop
manufactur
facil
nearli
